c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value
- 1 September 1998
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 51 (2), 109-119
- https://doi.org/10.1023/a:1005734429304
Abstract
The diagnostic value of a new tumor marker, c-erbB-2, was studied in the sera of 50 healthy subjects, 58 patients with benign breast diseases, and 413 patients with breast cancer (186 locoregional,...Keywords
This publication has 22 references indexed in Scilit:
- Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancerHuman Pathology, 1992
- HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma.Journal of Clinical Oncology, 1992
- Evaluation of Several Tumor Markers (MCA, CA 15.3, BCM and CA 549) in Tissue and Serum of Patients with Breast CancerPublished by Springer Nature ,1991
- c-erbB2 expression in correlation to other biological parameters of breast cancerZeitschrift für Krebsforschung und Klinische Onkologie, 1990
- Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic diseaseCancer, 1989
- HER-2/neu oncogene protein and prognosis in breast cancer.Journal of Clinical Oncology, 1989
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985
- Monoclonal antibodies against antigens on breast cancer cellsCellular and Molecular Life Sciences, 1985
- Differential Reactivity of a Novel Monoclonal Antibody (DF3) with Human Malignant versus Benign Breast TumorsHybridoma, 1984